Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Tribunal sided with Korean pharmas for Priligy case
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Aug 28, 2013 04:05:25
The Intellectual Property Tribunal sided with Korean pharmaceutical companies, Dong-A, Hanmi, Chong Kun Dang, and Kunil, on August 23, ruling that the patent on Menarini Korea’s Priligy’s use is not valid.

Priligy’s major patent goes off patent on July 28, 2015, but the patent on the use of a selective serotonin reuptake inhibitor for the treatment of sexual dysfunction was supposed to expire on June 5, 2021.

As the tribunal invalidated the patent on Priligy’s use, generic drugmakers won’t be likely to have any patent issue due to the Korea-U.S. free trade agreement.

Especially the first generic drug maker is allowed to monopolize the generic drug market for a certain period, based on the FTA rules.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com